Top Markets
Coin of the day
Hepion Pharmaceuticals, Inc. Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc.

HEPA
주식 순위 #38693
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is... Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
주가
$0.0601
시가총액
$699.79K
변동 (1일)
-14.14%
변동 (1년)
0.17%
국가
US
거래 Hepion Pharmaceuticals, Inc. (HEPA)

카테고리

Hepion Pharmaceuticals, Inc. (HEPA)의 주식 분할 이력
Hepion Pharmaceuticals, Inc. 주식 (심볼: HEPA)은 총 0회의 주식 분할을 거쳤습니다.
가장 최근의 분할은 Aug 14, 2026에 발생했습니다.
Aug 14, 2026 이전에 매수한 HEPA 주식 1주는 현재 0주의 HEPA 주식에 해당합니다.
주식 분할 목록
연도 주식 분할 배수 누적 배수
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 주식 분할
회사 주식 분할 횟수 누적 배수 국가
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE